

Shandong Dewish Medical Technology Co., Ltd. was established in 2007 and is located in Linyi City, Shandong Province. Its former name was DeVilbiss Health Care Equipment (Shandong) Co., Ltd. It is the earliest subsidiary established by DeVilbiss in China and also the only factory of DeVilbiss outside the United States. It specializes in manufacturing respiratory therapy products (such as nebulizers, oxygen generators, etc.) and sells them globally.
In 2015, DeVilbiss completed the acquisition with Drive Medical in the United States and was renamed: Drive DeVilbiss. The following year, DeVilbiss (Shandong) also underwent equity restructuring and was renamed: Shandong Dewish Medical Technology Co., Ltd., adopting the new brand logo "DeWish".
In order to carry forward the century-long spirit of striving and service innovation of DeVilbiss, DeVilbiss has defined its corporate slogan as "Building Love for a Century, Preserving Reputation for Generations". While fully adhering to the original technologies and processes, all core products have passed the latest inspection and certification by the National Medical Products Administration (NMPA) of China and obtained the "Medical Device Registration Certificate". In 2026, with a new brand image, they will re-enter the international market!
Dewish originated in the United States, grew up in China, and serves the world. It has both a century-long heritage and Chinese characteristics...



According to the clinical research data from Yisheng Information, particles ranging from 1 to 5 micrometers can cover the entire respiratory path from the large airways to the alveoli: particles of 2.5 to 5 micrometers mainly deposit in the bronchi and bronchioles (the treatment area of the large airways), while particles of 1 to 2.5 micrometers can penetrate the interstitium of the alveoli (the small airways treatment area). The precise settings of Devise at 2.2659 micrometers and 2.5588 micrometers precisely achieve the dual therapeutic effects of "anti-inflammatory in the large airways + repair of the small airways", not only taking into account the full-dimensional drug deposition in the respiratory tract and alveoli, but also providing a targeted tool for the deep penetration of lung diseases.

Dewish, with precise settings at 2.2659 μm and 2.5588 μm, precisely achieves the dual therapeutic effects of "anti-inflammation of the large airways + repair of the small airways", not only taking into account the full-dimensional drug deposition in the respiratory tract and alveoli, but also providing a targeted tool for the deep penetration of lung diseases.